Wegweiser
J Salmen, Georg Gdynia, Tobias R. Overbeck(Universitätsmedizin Göttingen), Sara Hugo, Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Hans‐Ulrich Schildhaus(University of Kassel), Martin Reck(German Center for Lung Research), Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Hartmut Link(Medizinische Hochschule Hannover), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Claudia M. Witt(National Center for Complementary and Integrative Health), Katja Schmitz(Goethe University Frankfurt), Andreas Stephan Lübbe, Martina Crysandt, Hans-Rudolf Raab, Marc-Andrea Bärtsch, Christoph Engelke, Carsten‐Oliver Sahlmann, Laura Kellner, Lorenz Trümper(University of Göttingen), Susanne Singer(Rostock University of Music and Theatre)
Cited by 0
Related Papers
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k